[go: up one dir, main page]

AR035857A1 - Fenilindoles; sus composiciones farmaceuticas y sus usos - Google Patents

Fenilindoles; sus composiciones farmaceuticas y sus usos

Info

Publication number
AR035857A1
AR035857A1 ARP020101341A ARP020101341A AR035857A1 AR 035857 A1 AR035857 A1 AR 035857A1 AR P020101341 A ARP020101341 A AR P020101341A AR P020101341 A ARP020101341 A AR P020101341A AR 035857 A1 AR035857 A1 AR 035857A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
unsubstituted
nhr2
nr2r3
Prior art date
Application number
ARP020101341A
Other languages
English (en)
Original Assignee
Novirio Pharmaceuticals Ltd
Univ Degli Studi Cagliari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novirio Pharmaceuticals Ltd, Univ Degli Studi Cagliari filed Critical Novirio Pharmaceuticals Ltd
Publication of AR035857A1 publication Critical patent/AR035857A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos derivados de fenilindol de fórmula (1) o una sal o profármaco aceptable para uso farmacéutico del mismo, en donde: (a) R1 es hidrógeno, acilo, -C(=O)H, -C(=W)H, -C(=O)R2, -C(=W)R2, -C(=O)OH, -C(=W)OH, -C(=O)OR2, -C(=W)OR2, -C(=O)SH, -C(=W)SH, -C(=O)SR2, -C(=W)SR2, -C(=O)NH2, -C(=W)NH2, -C(=O)NHR2, -C(=W)NHR2, -C(=O)NR2R3, -C(=W)NR2R3, -C(=W)NH-(CH2)p-(aminoácido) ó -(CH2)p-aminoácido; (b) R4', R5', R6', R7', R2", R3", R4", R5" y R6" son cada uno independientemente H, halo (F, Cl, Br ó I), -NO2, -CN, -OH, -OR2, -SH, -SR2, -NH2, -NHR2, -NR2R3, -NHSO2-alquilo C1-3, -NR2SO2-alquilo C1-3, -NHCO-alquilo C1-3, -NR2CO-alquilo C1-3, alquilo lineal o ramificado opcionalmente sustituido o insustituido, alquenilo o alquinilo (tal como un lineal o ramificado opcionalmente sustituido o insustituido alquilo C1-6, alquenilo C2-6 o alquinilo C2-6 y en particular CH3, CF3, bromuro de vinilo, -CR2R2-S(O)n-R3, -CR2R2NH2, -CR2R2NHR2, -CR2R2NR2R3 y -CR2R2-C(=O)R2), alcacilo, acilo opcionalmente sustituido o insustituido, -C(=O)H, -C(=W)H, -C(=O)R2, -C(=W)R2, -C(=O)OH, -C(=W)OH, -C(=O)OR2, -C(=W)OR2, -C(=O)SH, -C(=W)SH, -C(=O)SR2, -C(=W)SR2, -C(=O)NH2, -C(=W)NH2, -C(=O)NHR2, -C(=W)NHR2, -C(=O)NR2R3, -C(=W)NR2R3, -C(=W)NH(CH2)p-(aminoácido), un residuo de un aminoácido o -(CH2)p(aminoácido), donde si R5' es hidrógeno, F, Cl, Br, -NO2, -CN, -OR2, -NR2R2, -NHSO2-alquilo C1-3 ó -NHCO-alquilo C1-3, entonces al menos uno de R4', R6' y R7' no es hidrógeno; (c) Z es acilo opcionalmente sustituido o insustituido , -C(=O)NH2, -C(=W)NH2, -C(=O)NHR2, -C(=W)NHR2, -C(=O)NR2R3, -C(=W)NR2R3, -C(=W)NH(CH2)p-(aminoácido), un residuo de un aminoácido, -(CH2)p(aminoácido), -C(=O)R3, -C(=O)H, -C(=W)H, -C(=O)R2, -C(=W)R2, -C(=O)OR3, -C(=O)OH, -C(=W)OH, -C(=O)OR2, -C(=W)OR2, -C(=O)SH, -C(=W)SH, -C(=O)SR2, -C(=W)SR2, alquilo lineal o ramificado opcionalmente sustituido o insustituido, alquenilo o alquinilo (tal como un lineal o ramificado opcionalmente sustituido o insustituido alquilo C1-6, alquenilo C2-6 o alquinilo C2-6 y en particular CH3, CF3, bromuro de vinilo, -CR2R2-S(O)n-R3, -CR2R2NH2, -CR2R2NHR2, -CR2R2NR2R3 y -CR2R2-C(=O)R2), -CN o halo (F, Cl, Br ó I); (d) Y es O, S ó S(O)n; (e) cada W es independientemente O, S, -NH2, -NHR2, -NR2R2, -N-CN, -N-NH2, -N-NHR2, -N-NR2R3, -N-OH ó -N-OR2; (f) cada R2 es independientemente hidrógeno, o un alquilo inferior lineal o ramificado opcionalmente sustituido o insustituido, alquenilo o alquinilo (tal como un lineal o ramificado opcionalmente sustituido alquilo C1-3, alquenilo C2-4 o alquinilo C2-4, y en particular CH3, CF3, bromuro de vinilo, -CR2R2-S(O)n-R3, -CR2R2NH2, -CR2R2NHR2, -CR2R2NR2R3 y -CR2R2-C(=O)R2); (g) cada R3 es independientemente hidrógeno, alquilo lineal o ramificado opcionalmente sustituido o insustituido, alquenilo o alquinilo (tal como un lineal o ramificado opcionalmente sustituido o insustituido alquilo C1-6, alquenilo C2-6 o alquinilo C2-6 y en particular CH3, CF3, bromuro de vinilo, -CR2R2-S(O)n-R3, -CR2R2NH2, -CR2R2NHR2, -CR2R2NR2R3 y -CR2R2-C(=O)R2), arilo opcionalmente sustituido o insustituido (tal como fenilo), heterociclo opcionalmente sustituido o insustituido, opcionalmente sustituido o insustituido alquilarilo, opcionalmente sustituido o insustituido alquilheterociclo, opcionalmente sustituido o insustituido aralquilo, heterociclo opcionalmente sustituido o insustituido-alquilo; (h) cada n es independientemente 0, 1 ó 2; y (i) cada p es independientemente 0, 1, 2, 3, 4 ó 5; (j) donde si uno o más de los sustituyentes lineales o ramificados opcionalmente sustituidos alquilo, alquenilo, alquinilo, alquilo inferior, alquenilo inferior o alquinilo inferior, acilo, arilo, heterociclo, alcarilo, alc-heteroarilo, arilalquilo o alquilheterociclo está sustituido, entonces preferentemente está sustituido con uno o más entre halógenos (F, Cl, Br ó I), -OH, -OR2, -SH, -SR2, oxima, hidrazina, -C(=O)H, -C(=W)H, -C(=O)R2, -C(=W)R2, -C(=O)OH, -C(=W)OH, -C(=O)OR2, -C(=W)OR2, -C(=O)SH, -C(=W)SH, -C(=O)SR2, -C(=W)SR2, -C(=O)NH2, -C(=W)NH2, -C(=O)NHR2, -C(=W)NHR2, -C(=O)NR2R3, -C(=W)NR2R3, -NH2, -NHR2, -NR2R3, -NHSO2-alquilo C1-3, -NR2SO2-alquilo C1-3, -NHCO-alquilo C1-3, -NR2CO-alquilo C1-3, -S(O)n-R3, alcoxi C1-3, tioéter C1-3, un residuo de un aminoácido tal como -NH(CH2)p-(aminoácido) ó -C(=W)NH(CH2)p-(aminoácido). Los compuestos poseen actividad antiviral (es decir anti VIH) o bien se metabolizan en un compuesto que presenta tal actividad. Composiciones farmacéuticas que los contienen y sus usos en la fabricación de medicamentos.
ARP020101341A 2001-04-11 2002-04-11 Fenilindoles; sus composiciones farmaceuticas y sus usos AR035857A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28339301P 2001-04-11 2001-04-11

Publications (1)

Publication Number Publication Date
AR035857A1 true AR035857A1 (es) 2004-07-21

Family

ID=23085844

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101341A AR035857A1 (es) 2001-04-11 2002-04-11 Fenilindoles; sus composiciones farmaceuticas y sus usos

Country Status (10)

Country Link
US (3) US6710068B2 (es)
EP (1) EP1390029B1 (es)
AR (1) AR035857A1 (es)
AT (1) ATE451921T1 (es)
AU (1) AU2002254616B2 (es)
BR (1) BR0208790A (es)
CA (1) CA2444501C (es)
DE (1) DE60234760D1 (es)
TW (1) TWI294875B (es)
WO (1) WO2002083126A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1305313B1 (it) * 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
DE60234760D1 (de) * 2001-04-11 2010-01-28 Idenix Cayman Ltd Phenylindole zur behandlung von hiv
US7365090B2 (en) * 2002-08-07 2008-04-29 Idenix Pharmaceuticals, Inc. Substituted phenylindoles for the treatment of HIV
DE60329211D1 (de) 2002-10-31 2009-10-22 Metabasis Therapeutics Inc Cytarabin-monophosphate prodrugs
WO2004096147A2 (en) * 2003-04-28 2004-11-11 Idenix (Cayman) Limited Oxo-pyrimidine compounds
US7439268B2 (en) * 2003-07-18 2008-10-21 Idexx Laboratories Compositions containing prodrugs of florfenicol and methods of use
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
EP1799696B1 (en) * 2004-09-17 2008-11-12 IDENIX Pharmaceuticals, Inc. Phosphoindoles as hiv inhibitors
WO2006041961A1 (en) * 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
EP1809602B1 (en) * 2004-10-27 2008-10-29 Janssen Pharmaceutica N.V. Indole derivatives useful as progesterone receptor modulators
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
BRPI0706523A2 (pt) * 2006-01-13 2011-01-04 Wyeth Corp composto de fórmula i; composição farmacêutica; método de tratamento de distúrbios que estão relacionados com ou são afetados pela inibição da recaptação de norepinefrina, o receptor de 5-ht6 ou o receptor de 5-ht2a; método de tratamento de um distúrbio de aprendizado, de um distúrbio cognitivo, de um distúrbio de memória, de um distúrbio de personalidade, de um distúrbio comportamental, de um distúrbio de movimento, de um distúrbio neurodegenerativo, de abstinência de droga, de distúrbio de sono, de um distúrbio alimentar, de uma toxicidade de droga aguda, de um distúrbio cardiovascular, de uma disfunção sexual, de um distúrbio gastrintestinal, de um distúrbio genitourinário, de um distúrbio de dor, de um distúrbio nervoso ou de um distúrbio de sintoma vasomotor; método de tratamento de doença de alzheimer, de um distúrbio de deficiência da atenção, de esquizofrenia, de doença de parkinson, de discinésia tardia, de ataxia, de bradicinésia, de discinésias paroxìsmicas, de sìndrome da perna irrequieta, de tremor, de tremor essencial, de epilepsia, de apoplexia ou de trauma na cabeça; método de tratamento de doença arterial coronariana, de enfarte do miocárdio, de ataque isquêmico transitório, de angina, de fibrilação atrial, de agregação plaquetária, de risco de formação de coágulo sanguìneo, de sìndrome do intestino irritável, de constipação crÈnica, de doença do refluxo gastrintestinal, de dispepsia, de incontinência urinária por estresse ou de incontinência urinária de urgência; método de tratamento de depressão, de distúrbio compulsivo obsessivo, de tendência ao suicìdio, de distúrbio de ansiedade, de distúrbio bipolar, de distúrbio de pánico, de abstinência de nicotina, de abstinência de álcool, de abstinência de cocaìna, de abstinência de heroìna, de abstinência de anfetamina, de abstinência de drogas narcóticas, de insÈnia, de apnéia do sono, de narcolepsia, de distúrbio afetivo sanzonal, de sìndrome da perna irrequieta, de distúrbio de sono de turno de trabalho, de sìndrome da fase do sono retardada, de anorexia nervosa, de bulimia nervosa, de sìndrome do comer noturno, de superalimentação compulsiva, de sìndrome da fadiga crÈnica, de fibromialgia, de neuropatia de dor, de dor antinociceptiva, de sìndrome da dor crÈnica, de neuropatia diabética, de fogacho ou de suor noturno; e uso de um composto
ES2488922T3 (es) * 2006-09-29 2014-09-01 Idenix Pharmaceuticals, Inc. Fosfoindoles enantiómeramente puros como inhibidores del HIV
JP2010505834A (ja) * 2006-10-06 2010-02-25 メルク エンド カムパニー インコーポレーテッド 非ヌクレオシド系逆転写酵素阻害剤
US7550625B2 (en) * 2007-10-19 2009-06-23 Idexx Laboratories Esters of florfenicol
WO2009061856A1 (en) * 2007-11-09 2009-05-14 The Salk Instituite For Biological Studies Non-nucleoside reverse transcriptase inhibitors
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
CA2716332A1 (en) * 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
JP2013536200A (ja) 2010-08-20 2013-09-19 アミラ ファーマシューティカルス，インコーポレーテッド オートタキシン阻害剤およびその使用
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2714680B1 (en) 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
US9951026B2 (en) 2013-09-17 2018-04-24 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
WO2015042053A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
WO2015077503A1 (en) 2013-11-22 2015-05-28 Pharmakea, Inc. Autotaxin inhibitor compounds
WO2015123352A1 (en) 2014-02-13 2015-08-20 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
US9994600B2 (en) 2014-07-02 2018-06-12 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
AU2016268250B2 (en) 2015-05-27 2020-08-27 Sabre Therapeutics Llc Autotaxin inhibitors and uses thereof
AU2019207625A1 (en) 2018-01-09 2020-07-30 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3304019A1 (de) * 1983-02-07 1984-08-09 Kali-Chemie Pharma Gmbh, 3000 Hannover 3-acyloxy-1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4866084A (en) 1987-07-17 1989-09-12 Harbor Branch Oceanographic Institution, Inc. Topsentin compounds effective against viruses and certain tumors
GB8823693D0 (en) * 1988-10-08 1988-11-16 Hartopp R Injector cleaning apparatus
WO1993005020A1 (en) * 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
US5527819A (en) 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
US5124327A (en) 1991-09-06 1992-06-23 Merck & Co., Inc. HIV reverse transcriptase
DE4217964A1 (de) 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
US5633457A (en) * 1992-06-05 1997-05-27 Triangle Special Products Fuel injection cleaning and testing system and apparatus
WO1994019321A1 (en) * 1993-02-24 1994-09-01 Merck & Co., Inc. Inhibitors of hiv reverse transcriptase
US5489685A (en) 1994-05-12 1996-02-06 Merck & Co., Ltd. Method of synthesizing furo[2,3-b]pyridine carboxylic acid esters
WO1995032960A1 (en) 1994-05-31 1995-12-07 Mitsui Toatsu Chemicals, Incorporated Benzimidazole derivative
US5734081A (en) 1994-08-05 1998-03-31 Warner-Lambert Company Arylthio compounds
SK93297A3 (en) 1995-01-10 1998-02-04 Smithkline Beecham Spa Indole derivatives, method for their producing, pharmaceutical comosition containing the same, and their use
GB9614347D0 (en) 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
US5830894A (en) 1997-02-21 1998-11-03 Viropharma Incorporated Methods for preventing and treating pestivirus infection and associated diseases
US5935982A (en) 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
US20020091148A1 (en) * 2000-09-15 2002-07-11 Bamaung Nwe Y. 3-substituted indole antiproliferative angiogenesis inhibitors
DE60234760D1 (de) * 2001-04-11 2010-01-28 Idenix Cayman Ltd Phenylindole zur behandlung von hiv
US7365090B2 (en) * 2002-08-07 2008-04-29 Idenix Pharmaceuticals, Inc. Substituted phenylindoles for the treatment of HIV
US7406822B2 (en) * 2005-06-30 2008-08-05 Caterpillar Inc. Particulate trap regeneration system and control strategy
US7481048B2 (en) * 2005-06-30 2009-01-27 Caterpillar Inc. Regeneration assembly

Also Published As

Publication number Publication date
DE60234760D1 (de) 2010-01-28
US20040180888A1 (en) 2004-09-16
TWI294875B (en) 2008-03-21
WO2002083126A1 (en) 2002-10-24
US6710068B2 (en) 2004-03-23
BR0208790A (pt) 2004-03-30
EP1390029A1 (en) 2004-02-25
US20070293668A1 (en) 2007-12-20
TW200422291A (en) 2004-11-01
ATE451921T1 (de) 2010-01-15
EP1390029A4 (en) 2005-11-30
US20020193415A1 (en) 2002-12-19
CA2444501A1 (en) 2002-10-24
AU2002254616B2 (en) 2007-09-06
EP1390029B1 (en) 2009-12-16
CA2444501C (en) 2009-11-17

Similar Documents

Publication Publication Date Title
AR035857A1 (es) Fenilindoles; sus composiciones farmaceuticas y sus usos
AR055053A1 (es) Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas.
CA2475432A1 (en) 2,4,6-triamino-1,3,5-triazine derivative
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
PA8607001A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
DK0669968T3 (da) Aniliner som mærkningsmidler til mineralolier
CA2457054A1 (en) Activator of peroxisome proliferator-activated receptor .delta.
AR036091A1 (es) Compuestos heterociclicos,su procedimiento de preparacion, composiciones farmaceuticas y medicamentos, particularmente como agentes anti-bacterianos.
HUP0300138A2 (en) Cyclic amine derivatives as ccr5 antagonists, their production and use and pharmaceutical compositions containing them
PE20040241A1 (es) Inhibidores proteasa hiv, composiciones que los contienen y materiales para sus sintesis
HUP9900753A2 (hu) Kromon- és kumarinszármazékok, alkalmazásuk és a vegyületeket hatóanyagként tartalmazó fungicid készítmények
PA8792501A1 (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
CO5631432A2 (es) Derivados de n-[fenil(piepidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
ES2248498T3 (es) Derivados amidas, sulfonamidas o carbamatos aromaticos de acrilonitrilo y composiciones cosmeticas fotoprotectoras que los contienen.
HUP0100638A2 (hu) FP agonistákként alkalmazható aromás C16-C20-szubsztituált tetrahidroprosztaglandinok és ezeket tartalmazó gyógyszerkészítmények
ES2158726T3 (es) Utilizacion en tincion capilar de condensados de quinolina-5,8-dionas o de quinoxalina-5,8-dionas y de pirroles, anilinas o indoles sustituidos.
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
HUP0102099A2 (hu) Szubsztituált 2-oxo-alkánsav-[2-(indol-3-il)-etil]-amid-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
AR039689A1 (es) Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso
AR024939A1 (es) Compuestos derivados de hidantoina,tiohidantoina, pirimidinonas, tioxopirimidinonas, intermedirios, proceso para su preparacion y su uso de los mismos
AR036634A1 (es) Composicion de tenido que contiene un compuesto de para-aminofenol o para-fenilen diamina sustituido por un radical silanico
CO5540387A2 (es) Nuevos derivados de oxazolidinonas como antibacterianos

Legal Events

Date Code Title Description
FB Suspension of granting procedure